Pendapatan operasional sadurunge ngurangi amortisasi: COMPASS Pathways PLC (CMPS)

COMPASS Pathways plc (CMPS) maintains its leadership through patents for synthetic psilocybin and its influence within US psychiatry. The EBITDA financial metric on the GURU.Markets chart confirms this stage, where 0.00 shows the value of this parameter. However, geopolitical tensions are hindering global therapy trials, although its status as the primary innovator in psychedelics ensures deep trust in the brand from the medical community.

Bathi operasional EBITDA COMPASS Pathways plc (CMPS): kanggo periode 23.11.2025 - 10.11.2026

Ringkesan rincian data analitis COMPASS Pathways (CMPS)

- rega saham lan konsensus proyeksi valuasi:

Bagan kutipan COMPASS Corp|CMPS - Bagan rega target

- indikator kapitalisasi bursa perusahaan:

Kapitalisasi pasar COMPASS Pathways|CMPS - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data ekuitas miturut neraca:

Nilai Aset Bersih saben Saham COMPASS Pathways|CMPS - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih compasspathways.com|CMPS - Total Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

Rasio Kabeh Utang marang Dana Pribadi COMPASS Pathways plc|CMPS - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal COMPASS Pathways PLC|CMPS - Gunggung utang perusahaan|Utang marang nilai buku COMPASS Pathways|CMPS - Utang jangka dawa perusahaan|Utang jangka cendhak COMPASS Pathways|Indikator likuiditas cepet compasspathways.com

- rincian bathi lan kelipatan pasar:

CMPS - Bathi resik perusahaan|Bathi forward COMPASS Pathways plc|CMPS - Pangali P/E|Pangali Forward P/E compasspathways.com|CMPS - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan COMPASS Pathways|CMPS - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan COMPASS Pathways|CMPS - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan compasspathways.com|CMPS - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep COMPASS Pathways plc

Ringkesan analitik perusahaan:CMPS - COMPASS Corp

Anticipation of Phase 3 clinical trial results is driving the EBITDA trajectory for COMPASS Pathways plc (CMPS), reflecting the company's current lack of commercial sales. This indicator measures net cash flow from core operations before depreciation and interest, enabling an assessment of real operational efficiency and the capital burn rate, which is critical for high-risk biotech assets in the development stage.

Pesaing COMPASS Pathways plc (CMPS)

ALKS (Alkermes Corp) - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|AVDL - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Pendapatan operasional sadurunge ngurangi amortisasi atai.life ATAI|GHRS (GH Research) - Bathi operasional sadurunge ngurangi amortisasi|Bathi sadurunge bunga, pajak, lan amortisasi Mind Medicine (MindMed) Inc. (MNMD)|LBRX (LB Pharma) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi Bright Minds Corp (DRUG)|Bathi operasional EBITDA VNDA|CYBN (cybin.com) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Alto Neuroscience ANRO|NRx Pharmaceuticals Inc. (NRXP) - Bathi sadurunge bunga, pajak, lan amortisasi|Cingulate Corp - Bathi operasional EBITDA|Silo Pharma Inc. (SILO) - Bathi operasional sadurunge ngurangi amortisasi|chinapharmaholdings.com (CPHI) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi sadurunge bunga, pajak, lan amortisasi clearmindmedicine.com (CMND)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Psyence Biomedical|Bathi operasional sadurunge ngurangi amortisasi SciSparc Ltd. (SPRC)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Seelos Therapeutics, Inc (SEEL)|VRPX: Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi operasional EBITDA KRTX (Karuna Therapeutics)